{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"10.56","upperLimit":"37.61","value":"21.95"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"41"}],"units":"Participants"}],"description":"The percentage of successes will be estimated by the number of successes divided by the total number of evaluable patients. Exact binomial 95% confidence intervals for the true success percentages will be calculated.","dispersionType":"95% Confidence Interval","groups":[{"description":"CONDITIONING: Patients receive 56 mg/m\\^2 carfilzomib IV over 30 minutes on days -6, -5, -2, and -1. Patients also receive melphalan IV over 1 hour on days -4 and -3. TRANSPLANT: Patients undergo autologous stem cell transplant on day 0. Autologous Bone Marrow Transplantation: Undergo autologous stem cell transplant. Autologous Hematopoietic Stem Cell. Transplantation: Undergo autologous stem cell transplant, Carfilzomib: Given IV. Laboratory Biomarker Analysis: Correlative studies, Melphalan: Given IV","id":"OG000","title":"Dose Level 3"}],"paramType":"NUMBER","populationDescription":"All patients that received dose level 3 treatment, including phase 1: dose level 3 patients.","reportingStatus":"POSTED","timeFrame":"Up to 5 years","title":"Percentage of Patients With Complete Responses, Defined as a Complete Response Noted as the Objective Status on Two Consecutive Evaluations (Phase II)","type":"PRIMARY","unitOfMeasure":"percentage of patients"}